论文部分内容阅读
目的观察门冬胰岛素30联合口服降糖药治疗新发2型糖尿病疗效。方法选取餐后2h血糖≥13.9 mmol/L的2型糖尿病患者64例,随机分为2组,治疗组32例,早餐前一次皮下注射门冬胰岛素30,晚餐格列吡嗪和二甲双胍口服。对照组32例,格列吡嗪和二甲双胍口服,3次/d,观察治疗16周后一天7个时点血糖、糖化血红蛋白(HbAlc)、甘油三脂(TG)、低密度脂蛋白(LDL-C)及低血糖等不良事件。结果治疗组与对照组在治疗16周后血糖、HbAlc均显著下降(P<0.01),治疗组7个时点血糖显示空腹、早餐后2 h、午餐前、午餐后2 h、晚餐后2 h、睡前血糖共6个时点血糖控制效果优于对照组,差异有统计学意义(P<0.05)、晚餐前血糖差异无统计学意义(P>0.05)。HbAlc治疗组较对照组显著降低,差异有统计学意义(P<0.05)。TG、L-DL-C两组相近,差异无统计学意义(P>0.05),两组低血糖发生率差异无统计学意义(P>0.05)。结论门冬胰岛素30早餐前一次皮下注射联合口服降糖药治疗新发2型糖尿病优于口服降糖药治疗,且安全,依从性好。
Objective To observe the efficacy of insulin aspart 30 combined with oral hypoglycemic agents in the treatment of newly diagnosed type 2 diabetes mellitus. Methods Sixty-four patients with type 2 diabetes who had a blood glucose ≥ 13.9 mmol / L 2 hours after meal were randomly divided into two groups. The patients in the treatment group received insulin aspart 30 subcutaneously once a day before breakfast and oral glipizide and metformin respectively. In the control group, 32 cases were treated with glipizide and metformin orally three times a day. Blood glucose, HbA1c, TG, LDL-C were measured at the 7th day after treatment for 16 weeks. C) and hypoglycemia and other adverse events. Results The blood glucose and HbA1c in treatment group and control group were significantly decreased after 16 weeks of treatment (P <0.01). The fasting blood glucose in the treatment group was significantly higher at 2 hours after breakfast, 2 hours after breakfast, 2 hours after lunch, 2 hours after dinner (P <0.05). There was no significant difference in blood glucose before dinner (P> 0.05). HbAlc treatment group was significantly lower than the control group, the difference was statistically significant (P <0.05). There was no significant difference between TG and L-DL-C groups (P> 0.05). There was no significant difference in the incidence of hypoglycemia between the two groups (P> 0.05). Conclusion Aspart insulin 30 subcutaneous injection before breakfast combined with oral hypoglycemic agents in the treatment of newly diagnosed type 2 diabetes is better than oral hypoglycemic agents, and safe, good compliance.